GGrantIndex
← Leaderboards

Mihai Luchian Azoitei

Duke University

$6,996,690
Attributed
$6,996,690
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY202125
$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,996,690 · 3

By mechanism

R01$5,618,246 · 2
P01$1,378,444 · 1

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Engineering

Research focus

EngineeringDesignBindingScreeningProteinsSiteAffinityIn VivoLibrariesImmuneComputer ModelsMolecularSpecificityEpitopesBinding SitesStructureScaffolding ProteinUnited States National Institutes Of HealthScaffoldPreventMissionEnvironmentAntibodiesImmune Response

Grant awards (12)

Project 2 - Development of HLA-E-peptide antibodies for enhancing NK and CD8 killing of HIV infected CD4 T cells in vivo$1,378,444
P01 · FY2025 · AI · contact PI
High throughput platform to engineer light-controlled inhibitors against guanine exchange factors of the Dbl family$358,077
R01 · FY2025 · GM · contact PI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface$764,846
R01 · FY2024 · AI · contact PI
High throughput platform to engineer light-controlled inhibitors against guanine exchange factors of the Dbl family$359,408
R01 · FY2024 · GM · contact PI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface$770,343
R01 · FY2023 · AI · contact PI
High throughput platform to engineer light-controlled inhibitors against guanine exchange factors of the Dbl family$359,697
R01 · FY2023 · GM · contact PI
Acquisition of an iLas2 TIRF/FRAP imaging platform$250,000
R01 · FY2023 · GM · contact PI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface$186,406
R01 · FY2023 · AI · contact PI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface$789,339
R01 · FY2022 · AI · contact PI
In vivo Testing of Universal Influenza Vaccine Candidates at the Duke Regional Biocontainment Laboratory$569,014
R01 · FY2022 · AI · contact PI
High throughput platform to engineer light-controlled inhibitors against guanine exchange factors of the Dbl family$398,541
R01 · FY2022 · GM · contact PI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface$812,575
R01 · FY2021 · AI · contact PI